
People Incorporated proposes full takeover of MGM Resorts in cash deal
People Incorporated, the digital media and internet conglomerate formerly known as IAC (NASDAQ:IAC), announced Monday that it has submitted a non-binding proposal to the Board of Directors of MGM Resorts International (NYSE:MGM) to acquire all of the outstanding shares of the hospitality giant it does not currently own.
The all-cash offer is valued at $48.30 per share.
The buyout offer implies a premium of 24.1% over MGM’s 30-day volume-weighted average price (VWAP) ending May 29, 2026, and more than 30% against the company's 90-day VWAP.
The cash consideration also represents a 10.6% premium over MGM’s most recent closing market price.
People Incorporated currently maintains a significant minority foothold in MGM, holding approximately 26.1% of the casino operator's outstanding common stock.
Under the terms of the strategic proposal, the buyer intends to fund the multi-billion-dollar transaction through a mix of existing cash balances on hand at both firms, supplemented by newly committed debt and equity financing arrangements.
The company is targeting a post-closing equity ownership structure of just over 50.1%, effectively handing ultimate operational control of the global resort and gaming business to People Incorporated.
Remaining minority interests would continue to be held by other institutional co-investors.
The proposal arrives nearly six years after IAC initiated its foundational investment block in MGM, a move motivated by the durability of physical real estate assets in an increasingly digital and automated global economy.
The completion of the transaction remains subject to customary closing conditions.
Frequently asked questions
More from United States
Anthropic prices IPO above range at $83, sources say
Palo Alto Networks revenue advances to $3.44 billion, up 39%
Woodward records 22% sales growth in fiscal 2026 as revenue hits $4.4B
C3is reports $1.2 million Q3 net loss as revenue rises
Cosmos Health revenue hits $53.6 million, up 17.6%
Summit launches Phase III lung cancer trial for ivonescimab